journal article·2012-01

Dissolution Medium Responsive Simvastatin Release from Biodegradable Apatite Cements and the Therapeutic Effect in Osteoporosis Rats

Hideyuki Hamada, Hiroyuki Ohshima, Makoto Otsuka

Publisher page

Abstract

Bio-convertible artificial bone with slow release of anti-osteoporosis drug is useful to treat osteoporosis. Apatite cement containing 6% simvastatin (APD) had lower crystallinity than natural bone. In-vitro drug release tests in simulated body fluid (pH 7.8) and acetate buffer (pH 4.5) were performed at 37.0 C as physical models of osteoblast and osteoclast conditions (SOB and SOC). The device had a lower drug release rate under SOB, but significantly higher rates under SOC. The simvastatin release rate changed depending on dissolution media; drug release was repeated twice, and the rate under SOC was 15 times higher than under SOB. The device showed dissolution medium-responsive drug release. The device showed dissolution medium responsive drug release. After implantation of the APD in osteoporosis rats, the bone mineral density was evaluated by the x-ray computed tomography. The result indicated that the bone mineral density of APD implanted rat was significantly higher than that of control diseased. The result indicated that the device was therapeutically useful to bone regeneration.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Bone Tissue Engineering Materials · Bone Metabolism and Diseases · Bone health and osteoporosis research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Graduate School of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba - Japan

Graduate School of Pharmaceutical Sciences, Musashino University, Shinmachi, Nishi-Tokyo - Japan

References (31)

Show source-provided references
1. Baron R. · 1987 · 2 · 209
2. 10.1242/jcs.113.3.37710.1242/jcs.113.3.377 ↗
3. AlldredgeB.K., KimbleK., AnneM., YoungL., KradjanW.A., GuglielmoB.J. Applied therapeutics: the clinical use of drugs. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. pp. 101–3 (2009).
4. 10.2214/ajr.139.1.3910.2214/ajr.139.1.39 ↗
5. Calcium & Milk, Harvard School of Public Health. 2007. http://www.hsph.harvard.edu/nutritionsource/calcium.html. Retrieved 2008-01-28.
6. 10.1056/NEJMcp070721710.1056/NEJMcp0707217 ↗
7. National Prescribing Service (2009). Zoledronic Acid for osteoporosis, Medicines Update, Available at http://www.nps.org.au/consumers/publications/medicine_update/issues/Zoledronic_acid
8. 10.1007/s00198005023610.1007/s001980050236 ↗
9. 10.1172/JCI11258410.1172/JCI112584 ↗
10. 10.1210/jc.2004-177410.1210/jc.2004-1774 ↗
11. 10.1016/j.jocd.2007.03.10210.1016/j.jocd.2007.03.102 ↗
12. 10.1161/01.CIR.76.3.53410.1161/01.CIR.76.3.534 ↗
13. 10.1126/science.286.5446.194610.1126/science.286.5446.1946 ↗
14. 10.1007/s00223-001-2027-510.1007/s00223-001-2027-5 ↗
15. 10.1358/mf.2001.23.7.66212310.1358/mf.2001.23.7.662123 ↗
16. 10.1002/jcb.2007410.1002/jcb.20074 ↗
17. 10.1006/bbrc.2000.423210.1006/bbrc.2000.4232 ↗
18. 10.1210/en.2002-22068210.1210/en.2002-220682 ↗
19. 10.1046/j.1600-0501.2003.01015.x10.1046/j.1600-0501.2003.01015.x ↗
20. 10.1016/j.bjoms.2004.08.01410.1016/j.bjoms.2004.08.014 ↗
21. 10.3346/jkms.2005.20.3.43810.3346/jkms.2005.20.3.438 ↗
22. 10.1007/s10067-004-1053-x10.1007/s10067-004-1053-x ↗
23. 10.2165/00003495-199040040-0000710.2165/00003495-199040040-00007 ↗
24. 10.1186/1471-2474-4-810.1186/1471-2474-4-8 ↗
25. 10.1186/1471-2474-8-9810.1186/1471-2474-8-98 ↗
26. 10.1902/jop.2005.76.11.186110.1902/jop.2005.76.11.1861 ↗
27. 10.1002/jbm.82024060710.1002/jbm.820240607 ↗
28. 10.1002/jbm.b.3127710.1002/jbm.b.31277 ↗
29. 10.1211/002235799177253810.1211/0022357991772538 ↗
30. 10.1002/jps.260052121010.1002/jps.2600521210 ↗
31. 10.1248/cpb.38.350010.1248/cpb.38.3500 ↗